Renal Cell Carcinoma News

Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer

Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer

A cumulative-use analysis suggests that NSAIDs, ACEis, and SSRIs improve disease-specific outcomes among patients with kidney cancer, and further that NSAIDs improve overall survival.

FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma

FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma

Thirty to 40% of patients with RCC relapse a median of 2 years after nephrectomy. The majority of relapses occur within 5 years.

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma

A review of data from the CABOSUN and CheckMate-214 trials to determine the use of targeted therapy in metastatic renal cell carcinoma.

Nivolumab Improves 3-year Overall Survival in Previously Treated Renal Cell Carcinoma

Nivolumab Improves 3-year Overall Survival in Previously Treated Renal Cell Carcinoma

For CheckMate-025, 803 patients with RCC previously treated with anti-angiogenic therapy were assigned to receive IV nivolumab every 2 weeks or oral everolimus once daily.

miR-181a Overexpression May Have Tumorigenic Effects in Renal Cell Carcinoma

miR-181a Overexpression May Have Tumorigenic Effects in Renal Cell Carcinoma

Previous studies have associated miR-181a dysregulation with various cancers, such as acute lymphoblastic leukemia as well as colon, breast, and pancreatic cancers, but its role in ccRCC is unknown.

Adjuvant Sunitinib Prolongs Disease-free Survival in High-risk RCC Post-nephrectomy

Adjuvant Sunitinib Prolongs Disease-free Survival in High-risk RCC Post-nephrectomy

Patients in all subgroups who received adjuvant sunitinib had a DFS benefit compared with placebo, including patients who were at a higher risk of recurrence.

Sequence of Sunitinib and Nephrectomy May Not Affect Progression-free Rate in mRCC

Sequence of Sunitinib and Nephrectomy May Not Affect Progression-free Rate in mRCC

Researchers hypothesized that by reversing the order and administering targeted therapy prior to CN, tumor size would be reduced prior to surgery and lead to improved outcomes.

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.

First-line Cabozantinib Improves PFS in Clear Cell Renal Cell Carcinoma

First-line Cabozantinib Improves PFS in Clear Cell Renal Cell Carcinoma

In the open-label, phase 2 CABOSUN trial, 157 patients with untreated, locally advanced or metastatic clear cell RCC were randomly assigned to receive cabozantinib or sunitinib.

Non-inferiority of Sorafenib-Pazopanib Sequence Not Reached in Renal Cell Carcinoma

Non-inferiority of Sorafenib-Pazopanib Sequence Not Reached in Renal Cell Carcinoma

The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).

Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers

Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers

Cabozantinib and nivolumab (CaboNivo) with or without ipilimumab (Ipi) demonstrated manageable safety profiles and durable clinical activity.

Shorter Telomere Length Predicts Cancer in Patients With VHL

Shorter Telomere Length Predicts Cancer in Patients With VHL

Researchers evaluated telomere length samples from 184 patients with von Hippel-Lindau syndrome to determine whether shortened telomere length can predict cancer risk.

Higher Opioid Prescription Rates Among Survivors of Cancer

Higher Opioid Prescription Rates Among Survivors of Cancer

Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.

Nivolumab and Ipilimumab Well-tolerated, Active in Metastatic Renal Cell Carcinoma

Nivolumab and Ipilimumab Well-tolerated, Active in Metastatic Renal Cell Carcinoma

Combining nivolumab with ipilimumab is safe, efficacious, and potentially improves overall survival among patients with metastatic renal cell carcinoma.

Savolitinib Shows Promise for MET-driven Papillary Renal Cell Carcinoma

Savolitinib Shows Promise for MET-driven Papillary Renal Cell Carcinoma

Savolitinib was tolerable, safe, and may have treatment potential for patients with MET-driven papillary renal cell carcinoma.

Restoring ASPP1 May Improve Outcomes in Clear Cell RCC

Restoring ASPP1 May Improve Outcomes in Clear Cell RCC

Downregulation of apoptosis stimulating of p53 protein 1 confers drug resistance and permits tumor growth in clear cell renal cell carcinoma.

Toxicity-driven Sunitinib Dosing Improves Outcomes in RCC

Toxicity-driven Sunitinib Dosing Improves Outcomes in RCC

Toxicity-driven dosing of sunitinib improved response rates and survival compared with historical standard dosing among patients with metastatic renal cell carcinoma.

Plasma HGF Levels During Treatment Prognostic for Survival in RCC

Plasma HGF Levels During Treatment Prognostic for Survival in RCC

Patients with a decline in HGF levels had longer overall survival than those with high levels at baseline and at 4 weeks.

Two-to-One Sunitinib Schedule Fails To Reduce Toxicity

Two-to-One Sunitinib Schedule Fails To Reduce Toxicity

A modified dosing schedule of sunitinib did not improve adverse events rates among patients with metastatic renal cell carcinoma.

Characterization of Immune Cells in the RCC Tumor Microenvironment

Characterization of Immune Cells in the RCC Tumor Microenvironment

Overall, 3.5 million cells were analyzed and 17 major tumor-associated macrophage phenotypes were identified.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters